Related Experiment Video
Updated: May 19, 2026
Quantifying Pulmonary Microvascular Density in Mice Across Lobules
Published on: January 3, 2025
Effects of microvascular density on primary pulmonary non-Hodgkin's lymphoma (PPL)
Maopeng Yang1, Shu Zhao, Xaiosan Zhang
1Department of Medical Oncology, The Third Affiliated Hospital of Harbin Medical University, Haping Road 150 of Nangang District, Harbin, Heilongjiang Province 150081, China.
Abstract:
This study aims to analyze 30 cases of primary pulmonary lymphoma (PPL) including treatment as well as follow-up information during the past 10 years and to investigate the correlation between microvessel density (MVD) and survival in patients with PPL. We reviewed all patients from October 2000 to October 2010. Patient demographics such as survival, recurrence, time to follow-up, and treatment mode were recorded. We also assessed MVD in the pretreated pulmonary lymphoma tissues of 30 previously untreated patients using α-CD34 immunohistochemical staining. The median age of the 30 patients was 46.9 years. With a median follow-up of 4.3 years (range, 2 to 10 years), the 5-year overall survival (OS) rate was 57 % and progression-free survival (PFS) was 44 %. High MVD, elevated serum lactate dehydrogenase (LDH), and B symptoms was significantly correlated with clinical features and shorter PFS (P(MVD) = 0.021, P(LDH) = 0.023, and P(B symptoms) = 0.005) and OS (P(MVD) = 0.028, P(LDH) = 0.032, and P(B symptoms) = 0.001). Application of surgical treatment improved the PFS (P = 0.024) and OS(P = 0.028) of patients with stage IE disease (patients who were nodal negative). The patient's stage predicted the outcome and guides the use of treatments. Patients with high MVD measured in the microenvironment had worse PFS/OS than those with low MVD expression. Patients who had B symptoms or elevated serum LDH had poor prognosis. Patients with lymph node involvement (stage IIE or greater) had poor prognosis.
Insights
High microvessel density (MVD) and elevated lactate dehydrogenase (LDH) are linked to poorer survival in primary pulmonary lymphoma (PPL) patients. Surgical treatment improves outcomes for early-stage disease.
Area of Science:
- Oncology
- Pathology
- Immunohistochemistry
Background:
- Primary pulmonary lymphoma (PPL) is a rare malignancy.
- Understanding prognostic factors is crucial for patient management.
Purpose of the Study:
- To analyze treatment and survival data for 30 PPL cases over 10 years.
- To investigate the correlation between microvessel density (MVD) and patient survival in PPL.
Main Methods:
- Retrospective review of 30 PPL patients (October 2000 - October 2010).
- Assessment of MVD using α-CD34 immunohistochemical staining on pretreated tumor tissues.
- Analysis of patient demographics, treatment, survival, and recurrence data.
Main Results:
- The 5-year overall survival (OS) rate was 57%, and progression-free survival (PFS) was 44%.
- High MVD, elevated serum lactate dehydrogenase (LDH), and B symptoms correlated with shorter PFS and OS (P < 0.05).
- Surgical treatment improved PFS and OS in stage IE PPL (nodal negative).
Conclusions:
- MVD is a significant prognostic marker in PPL, with high MVD associated with worse outcomes.
- Elevated LDH and B symptoms indicate a poor prognosis.
- Staging and surgical intervention are key factors in guiding PPL treatment and predicting outcomes.